{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:45:19Z","timestamp":1780357519074,"version":"3.54.1"},"reference-count":340,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs) are unique hematopoietic stem cell disorders sharing mutations that constitutively activate the signal-transduction pathways involved in haematopoiesis. They are characterized by stem cell-derived clonal myeloproliferation. The key MPNs comprise chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). CML is defined by the presence of the Philadelphia (Ph) chromosome and BCR-ABL1 fusion gene. Despite effective cytoreductive agents and targeted therapy, complete CML\/MPN stem cell eradication is rarely achieved. In this review article, we discuss the novel agents and combination therapy that can potentially abnormal hematopoietic stem cells in CML and MPNs and the CML\/MPN stem cell-sustaining bone marrow microenvironment.<\/jats:p>","DOI":"10.3390\/ijms22020659","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T11:36:11Z","timestamp":1610364971000},"page":"659","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"22","author":[{"given":"Yammy","family":"Yung","sequence":"first","affiliation":[{"name":"Division of Haematology, Medical Oncology and Haemopoietic Stem Cell Transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Haematology, Medical Oncology and Haemopoietic Stem Cell Transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu-Tung","family":"Chu","sequence":"additional","affiliation":[{"name":"Division of Haematology, Medical Oncology and Haemopoietic Stem Cell Transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui-Kwan","family":"Yip","sequence":"additional","affiliation":[{"name":"Division of Haematology, Medical Oncology and Haemopoietic Stem Cell Transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4893","authenticated-orcid":false,"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Haematology, Medical Oncology and Haemopoietic Stem Cell Transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms\u2014Trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2017-05-783845","article-title":"hsa-mir183\/EGR1-mediated regulation of E2F1 is required for CML stem\/progenitor cell survival","volume":"131","author":"Pellicano","year":"2018","journal-title":"Blood"},{"key":"ref_5","first-page":"1166","article-title":"The differential diagnosis of classical myeloproliferative neoplasms (MPN): The updated WHO criteria","volume":"60","author":"Kvasnicka","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","article-title":"Update from the latest WHO classification of MPNs: A user\u2019s manual","volume":"2016","author":"Passamonti","year":"2016","journal-title":"Hematology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","article-title":"The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"22","author":"Pophali","year":"2016","journal-title":"Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: From origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Grabek, J., Straube, J., Bywater, M., and Lane, S.W. (2020). MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. Cells, 9.","DOI":"10.3390\/cells9081901"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2019.317","article-title":"Recent insights regarding the molecular basis of myeloproliferative neoplasms","volume":"35","author":"Jang","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Allegra, A., Pioggia, G., Tonacci, A., Casciaro, M., Musolino, C., and Gangemi, S. (2020). Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR\u2013ABL-Negative Myeloproliferative Neoplasm. Antioxidants, 9.","DOI":"10.3390\/antiox9111037"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: The root of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Protein Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation-2017.1.115","article-title":"Novel approaches to therapy in CML","volume":"2017","author":"Bhatia","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic Myeloid Leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","journal-title":"Hemasphere"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Valent, P., Sadovnik, I., Eisenwort, G., Bauer, K., Herrmann, H., Gleixner, K.V., Schulenburg, A., Rabitsch, W., Sperr, W.R., and Wolf, D. (2019). Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174233"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2020.09.186","article-title":"Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells","volume":"90","author":"Tanaka","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4252\/wjsc.v11.i8.476","article-title":"Bone marrow microenvironment: The guardian of leukemia stem cells","volume":"11","author":"Houshmand","year":"2019","journal-title":"World J. Stem Cells"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/15680096113139990088","article-title":"Autophagy in chronic myeloid leukaemia: Stem cell survival and implication in therapy","volume":"13","author":"Helgason","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sctm.17-0175","article-title":"Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment","volume":"7","author":"Arrigoni","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41375-018-0252-4","article-title":"Targeting quiescent leukemic stem cells using second generation autophagy inhibitors","volume":"33","author":"Baquero","year":"2019","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of \u03b2-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/BLCTT.S228815","article-title":"Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells","volume":"9","author":"Maffeo","year":"2019","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","author":"Herrmann","year":"2012","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities","volume":"11","author":"Chaar","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1089\/scd.2019.0117","article-title":"The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation","volume":"28","author":"Jiang","year":"2019","journal-title":"Stem Cells Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/724360","article-title":"Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells","volume":"2013","author":"Hamad","year":"2013","journal-title":"Stem Cells Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph + chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1002\/ajh.25106","article-title":"Nilotinib induced bone marrow CD34+\/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia","volume":"93","author":"Pungolino","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/jcp.23029","article-title":"Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients","volume":"227","author":"Ciarcia","year":"2012","journal-title":"J. Cell Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jcmm.12873","article-title":"Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor","volume":"20","author":"Corrado","year":"2016","journal-title":"J. Cell Mol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/sci.2018.03.05","article-title":"Targeting chronic myeloid leukemia stem cells: Can transcriptional program be a druggable target for cancers?","volume":"5","author":"Masamoto","year":"2018","journal-title":"Stem Cell Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jcp.25118","article-title":"Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia","volume":"231","author":"Ciarcia","year":"2016","journal-title":"J. Cell Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_44","first-page":"4178","article-title":"Expression Levels of PD-1 on CD8+ T Cells in Chronic Myeloid Leukemia with and without BCR-ABL1 kinase Mutation","volume":"130","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00262-020-02617-5","article-title":"Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication","volume":"69","author":"Lee","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2040620719826444","DOI":"10.1177\/2040620719826444","article-title":"Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia","volume":"10","author":"Molica","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14728214.2018.1445717","article-title":"Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia","volume":"23","author":"Kavanagh","year":"2018","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106337","DOI":"10.1016\/j.leukres.2020.106337","article-title":"Novel therapeutic approaches in chronic myeloid leukemia","volume":"91","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Lindner","year":"2003","journal-title":"Apoptosis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1182\/blood.V87.9.3883.bloodjournal8793883","article-title":"Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia","volume":"87","author":"Bhatia","year":"1996","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nature12612","article-title":"Arteriolar niches maintain haematopoietic stem cell quiescence","volume":"502","author":"Kunisaki","year":"2013","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Chronic Myeloid Leukemia Trialists\u2019 Collaborative Group (1997). Interferon Alfa Versus Chemotherapy for Chronic Myeloid Leukemia: A Meta-analysis of Seven Randomized Trials. JNCI J. Natl. Cancer Inst., 89, 1616\u20131620.","DOI":"10.1093\/jnci\/89.21.1616"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"How, J., and Hobbs, G. (2020). Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature. Cancers, 12.","DOI":"10.3390\/cancers12071954"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.exphem.2010.03.005","article-title":"Interferon-\u03b1 targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway","volume":"38","author":"Lu","year":"2010","journal-title":"Exp. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: A report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"57","author":"Larsen","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Skov, V. (2020). Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers, 12.","DOI":"10.3390\/cancers12082194"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: Minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo","volume":"8","author":"Verger","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41375-018-0295-6","article-title":"JAK2V617F but not CALR mutations confer increased molecular responses to interferon-\u03b1 via JAK1\/STAT1 activation","volume":"33","author":"Czech","year":"2019","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1182\/blood-2018-99-114744","article-title":"Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN","volume":"132","author":"Mosca","year":"2018","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kj\u00e6r, L., Cordua, S., Holmstr\u00f6m, M.O., Thomassen, M., Kruse, T.A., Pallisgaard, N., Larsen, T.S., De Stricker, K., Skov, V., and Hasselbalch, H.C. (2016). Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165336"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","article-title":"Givinostat: An emerging treatment for polycythemia vera","volume":"29","author":"Chifotides","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor\u2013Na\u00efve Patients With Myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Talpaz, M., and Kiladjian, J.-J. (2020). Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia.","DOI":"10.1038\/s41375-020-0954-2"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/13543784.2020.1751121","article-title":"Investigational non-JAK inhibitors for chronic phase myelofibrosis","volume":"29","author":"Bankar","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation","volume":"23","author":"Panagiota","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ejh.13318","article-title":"Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation","volume":"103","author":"Mannina","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/leu.2014.326","article-title":"PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation","volume":"29","author":"Mian","year":"2015","journal-title":"Leukemia"},{"key":"ref_91","first-page":"289","article-title":"PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells","volume":"55","author":"Ivanova","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2019-127951","article-title":"PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I","volume":"134","author":"Turkina","year":"2019","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3892\/or.2015.4456","article-title":"The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)","volume":"35","author":"Mirone","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428194.2016.1243676","article-title":"miRNAs in chronic myeloid leukemia: Small molecules, essential function","volume":"58","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"32493","DOI":"10.1038\/srep32493","article-title":"Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells","volume":"6","author":"Agatheeswaran","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-020-00183-1","article-title":"Expression differences of miR-142-5p between treatment-na\u00efve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance","volume":"9","author":"Bruckmueller","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"49451","DOI":"10.18632\/oncotarget.17706","article-title":"Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells","volume":"8","author":"Salati","year":"2017","journal-title":"Oncotarget"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5507\/bp.2014.037","article-title":"The miR-29 family in hematological malignancies","volume":"159","author":"Fiserova","year":"2015","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","article-title":"BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia","volume":"103","author":"Srutova","year":"2018","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s13577-020-00367-1","article-title":"MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy","volume":"33","author":"Li","year":"2020","journal-title":"Hum. Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exphem.2018.09.001","article-title":"miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2","volume":"68","author":"Pan","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/cas.12339","article-title":"Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors","volume":"105","author":"Nishioka","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","article-title":"Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment","volume":"360","author":"Modai","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3892\/ijo.2017.3934","article-title":"Hydroxychloroquine sensitizes chronic myeloid leukemia cells to V\u03b39V\u03b42 T cell-mediated lysis independent of autophagy","volume":"50","author":"Han","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/leu.2011.273","article-title":"An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-\u03b1 and cAMP\/PKA pathways","volume":"26","author":"Lv","year":"2012","journal-title":"Leukemia"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3892\/or.2014.3078","article-title":"Overexpression of microRNA-143 inhibits growth and induces apoptosis in human leukemia cells","volume":"31","author":"Shen","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood.V128.22.3060.3060","article-title":"Downregulation of Mir-146a-5p, Mir-99b-5p, Mir-143-3p, Mir-10a-5p and Mir-151a-3p Associated with PI3K\/AKT, p53, NF-Kb, and Fanconi Anemia\/BRCA Signaling Pathways Are Observed in Imatinib-Resistant Chronic Myeloid Leukemia Patients without Detectable BCR-ABL kinase Domain Mutations","volume":"128","author":"Yap","year":"2016","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3324\/haematol.2009.020636","article-title":"Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia","volume":"95","author":"Flamant","year":"2010","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4149\/neo_2015_115","article-title":"microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia","volume":"62","author":"Jurkovicova","year":"2015","journal-title":"Neoplasma"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2010.257","article-title":"Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells","volume":"25","author":"Modi","year":"2011","journal-title":"Leukemia"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"43662","DOI":"10.18632\/oncotarget.18216","article-title":"Targeting BCR-ABL+ stem\/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/blood.V128.22.4239.4239","article-title":"BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia","volume":"128","author":"Ohanian","year":"2016","journal-title":"Blood"},{"key":"ref_114","first-page":"1381","article-title":"Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes","volume":"25","author":"Peng","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1878-0261.12186","article-title":"Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-\u03baB pathways in a model of chronic myeloid leukemia","volume":"12","author":"Chorzalska","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Jacquel, A., Luciano, F., Robert, G., and Auberger, P. (2018). Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102991"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jcb.25559","article-title":"Targeting the mTOR Pathway in Leukemia","volume":"117","author":"Dinner","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Frazzi, R., and Guardi, M. (2017). Cellular and Molecular Targets of Resveratrol on Lymphoma and Leukemia Cells. Molecules, 22.","DOI":"10.3390\/molecules22060885"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.18632\/oncotarget.413","article-title":"AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications","volume":"2","author":"Vakana","year":"2011","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/cbdd.13013","article-title":"New insights into antidiabetic drugs: Possible applications in cancer treatment","volume":"90","author":"Samadi","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fendo.2018.00446","article-title":"Metformin, an Anti-diabetic Drug to Target Leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front. Endocrinol"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/CAD.0000000000000266","article-title":"The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell","volume":"26","author":"Shi","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/aps.2014.132","article-title":"Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/0008-5472.CAN-09-3537","article-title":"Resveratrol Promotes Autophagic Cell Death in Chronic Myelogenous Leukemia Cells via JNK-Mediated p62\/SQSTM1 Expression and AMPK Activation","volume":"70","author":"Puissant","year":"2010","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1038\/s41598-018-26102-3","article-title":"AICAR inhibits NF\u03baB DNA binding independently of AMPK to attenuate LPS-triggered inflammatory responses in human macrophages","volume":"8","author":"Kirchner","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.3324\/haematol.2019.229997","article-title":"CD34(+) acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax","volume":"105","author":"Mattes","year":"2020","journal-title":"Haematologica"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1-BCR-ABL-JAK2 Complex","volume":"105","author":"Chen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V128.22.1892.1892","article-title":"A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease","volume":"128","author":"Sweet","year":"2016","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1182\/blood-2018-99-119476","article-title":"Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia","volume":"132","author":"Dao","year":"2018","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1182\/blood-2019-127272","article-title":"A Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia with Minimal Residual Disease While on Therapy with Imatinib","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fonc.2019.00665","article-title":"New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia","volume":"9","author":"Westerweel","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1038\/bcj.2015.109","article-title":"PPAU\u2265 ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells","volume":"6","author":"SeferzDska","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cbdd.12737","article-title":"Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies","volume":"88","author":"Yousefi","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/leu.2017.14","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"31","author":"Eiring","year":"2017","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Brachet-Botineau, M., Polomski, M., Neubauer, H.A., Juen, L., H\u00e9dou, D., Viaud-Massuard, M.-C., Pri\u00e9, G., and Gouilleux, F. (2020). Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers, 12.","DOI":"10.3390\/cancers12010240"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2017.08.001","article-title":"Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1","volume":"21","author":"Li","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1002\/cncr.32130","article-title":"Antitumor efficacy of arsenic\/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors","volume":"125","author":"Itani","year":"2019","journal-title":"Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41467-017-02427-x","article-title":"A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche","volume":"9","author":"Guarnerio","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_147","first-page":"1018","article-title":"Arsenic Trioxide for Non Acute Promyelocytic Leukemia Hematological Malignancies: A New Frontier","volume":"1","author":"Zhou","year":"2014","journal-title":"J. Blood Disord."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood-2005-06-2318","article-title":"Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia","volume":"107","author":"Du","year":"2006","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-015-0158-4","article-title":"The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis","volume":"15","author":"Wang","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.28427","article-title":"Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha","volume":"134","author":"Iskandarani","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hon.2786","article-title":"A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1","volume":"28","author":"Heibl","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3324\/haematol.2019.234898","article-title":"Defining niche interactions to target chronic myeloid leukemia stem cells","volume":"105","author":"Mitchell","year":"2020","journal-title":"Haematologica"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/scd.2014.0551","article-title":"Evidence that \u03b27 Integrin Regulates Hematopoietic Stem Cell Homing and Engraftment Through Interaction with MAdCAM-1","volume":"25","author":"Murakami","year":"2016","journal-title":"Stem Cells Dev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3324\/haematol.2018.212365","article-title":"The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin\u2014SCL\/TAL1\u2014CD44 axis","volume":"105","author":"Godavarthy","year":"2020","journal-title":"Haematologica"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Windisch, R., Pirschtat, N., Kellner, C., Chen-Wichmann, L., Lausen, J., Humpe, A., Krause, D., and Wichmann, C. (2019). Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11030311"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4161\/19336918.2014.968501","article-title":"The role of novel and known extracellular matrix and adhesion molecules in the homeostatic and regenerative bone marrow microenvironment","volume":"8","author":"Klamer","year":"2014","journal-title":"Cell Adhes. Migr."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3389\/fcell.2020.00607","article-title":"Leukemia Stem Cell Release From the Stem Cell Niche to Treat Acute Myeloid Leukemia","volume":"8","author":"Villatoro","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2016.0023","article-title":"Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang","volume":"13","author":"Zhou","year":"2016","journal-title":"Cancer Biol. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: Insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood-2016-10-741009","article-title":"Twisting IL-1 signaling to kill CML stem cells","volume":"128","author":"Stramucci","year":"2016","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2013-11-538694","article-title":"Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche","volume":"123","author":"Krause","year":"2014","journal-title":"Blood"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"TPS7066","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7066","article-title":"A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed\/refractory acute myeloid leukemia","volume":"37","author":"DeAngelo","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.stem.2019.02.018","article-title":"Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells","volume":"24","author":"Agarwal","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13287-017-0765-1","article-title":"CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells","volume":"9","author":"Melo","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.25958","article-title":"Aptamers in the Therapeutics and Diagnostics Pipelines","volume":"8","author":"Kaur","year":"2018","journal-title":"Theranostics"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"109973","DOI":"10.18632\/oncotarget.22409","article-title":"Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition","volume":"8","author":"Weisberg","year":"2017","journal-title":"Oncotarget"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000354229","article-title":"Current Clinical Indications for Plerixafor","volume":"40","author":"Fruehauf","year":"2013","journal-title":"Transfus. Med. Hemother."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood-2011-05-355396","article-title":"Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML","volume":"120","author":"Agarwal","year":"2012","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.tips.2015.03.003","article-title":"Hypoxia-inducible factors in cancer stem cells and inflammation","volume":"36","author":"Peng","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12013-014-0434-2","article-title":"HIF-\u03b1 Promotes Chronic Myelogenous Leukemia Cell Proliferation by Upregulating p21 Expression","volume":"72","author":"Chen","year":"2015","journal-title":"Cell Biochem. Biophys."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.kjms.2015.03.002","article-title":"Emerging roles of hypoxia-inducible factors and reactive oxygen species in cancer and pluripotent stem cells","volume":"31","author":"Saito","year":"2015","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.exphem.2012.01.003","article-title":"Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through \u03b2-catenin signaling","volume":"40","author":"Su","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood.V124.21.4539.4539","article-title":"Dasatinib Plus Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) with Resistance or Suboptimal Response to a Prior Tyrosine Kinase Inhibitor (TKI): Phase I Study CA180323","volume":"124","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","article-title":"Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI","volume":"129","author":"Agarwal","year":"2017","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood.V126.23.54.54","article-title":"Inhibition of CML Stem Cell Renewal By the Porcupine Inhibitor WNT974","volume":"126","author":"Agarwal","year":"2015","journal-title":"Blood"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3389\/fonc.2019.00532","article-title":"The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Grassi","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Pippa, R., and Odero, M.D. (2020). The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias. Cells, 9.","DOI":"10.3390\/cells9030544"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.3324\/haematol.2014.115691","article-title":"c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia","volume":"100","author":"Lucas","year":"2015","journal-title":"Haematologica"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s10495-013-0882-y","article-title":"FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors","volume":"18","author":"Kiyota","year":"2013","journal-title":"Apoptosis"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-015-0407-0","article-title":"BCR\/ABL1 and BCR are under the transcriptional control of the MYC oncogene","volume":"14","author":"Sharma","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia","volume":"20","author":"Agarwal","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib","volume":"9","author":"Albajar","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"58","DOI":"10.14715\/cmb\/2018.64.9.9","article-title":"The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: A review","volume":"64","author":"Keramatinia","year":"2018","journal-title":"Cell Mol. Biol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/leusup.2012.23","article-title":"Biology of CML stem cells: The basis for clinical heterogeneity?","volume":"1","author":"Goldman","year":"2012","journal-title":"Leuk. Suppl."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1002\/jcb.27744","article-title":"Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment","volume":"120","author":"Saydam","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/bjh.15861","article-title":"Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy","volume":"186","author":"Olszewski","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/stem.2845","article-title":"Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil","volume":"36","author":"Busque","year":"2018","journal-title":"Stem Cells"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Valent, P., Kern, W., Hoermann, G., Milosevic Feenstra, J., Sotlar, K., Pfeilst\u00f6cker, M., Germing, U., Sperr, W., Reiter, A., and Wolf, D. (2019). Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030789"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40778-018-0133-9","article-title":"Clonal Hematopoiesis in Aging","volume":"4","author":"Park","year":"2018","journal-title":"Curr. Stem Cell Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MOH.0000000000000465","article-title":"Age-related clonal hematopoiesis: Implications for hematopoietic stem cell transplantation","volume":"25","author":"Abelson","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: A novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cellimm.2019.02.001","article-title":"3rd, Emerging roles of and therapeutic strategies targeting BRD4 in cancer","volume":"337","author":"White","year":"2019","journal-title":"Cell Immunol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood-2018-99-111126","article-title":"BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML","volume":"132","author":"Peter","year":"2018","journal-title":"Blood"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1172\/JCI73941","article-title":"The role for autophagy in cancer","volume":"125","author":"White","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/cas.12386","article-title":"Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16","volume":"105","author":"Ueda","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Rinke, J., Chase, A., Cross, N.C.P., Hochhaus, A., and Ernst, T. (2020). EZH2 in Myeloid Malignancies. Cells, 9.","DOI":"10.3390\/cells9071639"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"37974","DOI":"10.18632\/oncotarget.16467","article-title":"Role of EZH2 in cancer stem cells: From biological insight to a therapeutic target","volume":"8","author":"Wen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Bavaro, L., Martelli, M., Cavo, M., and Soverini, S. (2019). Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246141"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13148-020-00839-z","article-title":"Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL\/MYC-signaling: Effect on imatinib resistance and stem cells","volume":"12","author":"Lernoux","year":"2020","journal-title":"Clin. Epigenet."},{"key":"ref_215","first-page":"4990","article-title":"Chidamide, a Novel Histone Deacetylase Inhibitor, Combined with Imatinib Induces Synthetic Lethality in Drug-Resistant Chronic Myeloid Leukemia","volume":"130","author":"He","year":"2017","journal-title":"Blood"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.gendis.2019.06.002","article-title":"PRMT5 in gene regulation and hematologic malignancies","volume":"6","author":"Zhu","year":"2019","journal-title":"Genes Dis."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"108790","DOI":"10.1016\/j.biopha.2019.108790","article-title":"Role of protein arginine methyltransferase 5 in human cancers","volume":"114","author":"Xiao","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1172\/JCI85239","article-title":"Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia","volume":"126","author":"Jin","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"25217","DOI":"10.18632\/oncotarget.4611","article-title":"Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes I\u03baB\u03b1 mediated p53 nuclear exclusion","volume":"6","author":"Crivellaro","year":"2015","journal-title":"Oncotarget"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/CAD.0000000000000651","article-title":"RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-\u03baB signaling pathways","volume":"29","author":"Mobaraki","year":"2018","journal-title":"Anticancer Drugs"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.bbrc.2011.11.161","article-title":"Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation","volume":"417","author":"Ma","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood-2018-99-115709","article-title":"SIRT1 Mediates Enhanced Mitochondrial Oxidative Phosphorylation in Chronic Myelogenous Leukemia Stem Cells","volume":"132","author":"Abraham","year":"2018","journal-title":"Blood"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/10428194.2016.1272682","article-title":"Induction of p53 suppresses chronic myeloid leukemia","volume":"58","author":"Peterson","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/jmcb\/mjz075","article-title":"Inhibition of p53 inhibitors: Progress, challenges and perspectives","volume":"11","author":"Sanz","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3324\/haematol.2019.246306","article-title":"Recruiting TP53 to target chronic myeloid leukemia stem cells","volume":"105","author":"Grant","year":"2020","journal-title":"Haematologica"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Yun, C.W., and Lee, S.H. (2018). The Roles of Autophagy in Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113466"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.2147\/CMAR.S202442","article-title":"The molecular mechanisms underlying BCR\/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy","volume":"11","author":"Huang","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13046-017-0512-6","article-title":"Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia","volume":"36","author":"Lu","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08998280.2006.11928154","article-title":"Tigecycline (Tygacil): The First in the Glycylcycline Class of Antibiotics","volume":"19","author":"Greer","year":"2006","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-cancerbio-041816-122338","article-title":"The Role of Autophagy in Cancer","volume":"1","author":"Mancias","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/10428194.2010.546913","article-title":"Inhibition of autophagy: A new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors","volume":"52","author":"Calabretta","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41375-019-0700-9","article-title":"A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease","volume":"34","author":"Horne","year":"2020","journal-title":"Leukemia"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.leukres.2018.07.011","article-title":"Nivolumab to control molecular response in chronic myeloid leukemia","volume":"72","author":"Rousselot","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/21645515.2018.1551671","article-title":"Product review: Avelumab, an anti-PD-L1 antibody","volume":"15","author":"Collins","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/leu.2017.78","article-title":"Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis","volume":"31","author":"Mosoyan","year":"2017","journal-title":"Leukemia"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","article-title":"Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood-2018-99-115163","article-title":"Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels","volume":"132","author":"Mascarenhas","year":"2018","journal-title":"Blood"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2017.177600","article-title":"Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms","volume":"103","author":"Hobbs","year":"2018","journal-title":"Haematologica"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2019-131217","article-title":"Results from a Phase 1\/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed\/Refractory Myelofibrosis","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2019-123244","article-title":"A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis","volume":"134","author":"Pettit","year":"2019","journal-title":"Blood"},{"key":"ref_251","unstructured":"Hergert, J. (2019, November 30). First-in-Class LSD1 Inhibitor Elicits Clinical Activity in Advanced Myelofibrosis. Available online: onclive.com\/view\/first-in-class-lsd1-inhibitor-elicits-clinical-activity-in-advanced-myelofibrosis."},{"key":"ref_252","unstructured":"Hugh Rienhoff, M. (2020). IMG-7289 in Patients With Essential Thrombocythemia."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: A two-part Phase Ib\/II study","volume":"34","author":"Rambaldi","year":"2020","journal-title":"Leukemia"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"Deangelo","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_255","unstructured":"(2019). A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3324\/haematol.2018.200014","article-title":"The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: Results of phase II study SAKK 33\/14","volume":"104","author":"Drexler","year":"2019","journal-title":"Haematologica"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2019-122546","article-title":"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-140441","article-title":"Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study","volume":"136","author":"Bose","year":"2020","journal-title":"Blood"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-19-1481","article-title":"Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?","volume":"25","author":"Piszczatowski","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.3324\/haematol.2018.209965","article-title":"Results from HARMONY: An open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis","volume":"104","author":"Durrant","year":"2019","journal-title":"Haematologica"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: From structures to applications","volume":"12","author":"Esteller","year":"2017","journal-title":"Epigenetics"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccell.2017.12.007","article-title":"BET\u2019ing on Dual JAK\/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms","volume":"33","author":"Jiang","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1084\/jem.20151121","article-title":"The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition","volume":"213","author":"Sashida","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu","year":"2014","journal-title":"Blood"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.12688\/f1000research.18581.1","article-title":"Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology","volume":"8","author":"Eran","year":"2019","journal-title":"F1000Research"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1182\/blood-2019-123836","article-title":"An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor","volume":"134","author":"McLornan","year":"2019","journal-title":"Blood"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2019-123546","article-title":"A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera","volume":"134","author":"Gotlib","year":"2019","journal-title":"Blood"},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Kuykendall, A.T., Horvat, N.P., Pandey, G., Komrokji, R., and Reuther, G.W. (2020). Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers, 12.","DOI":"10.3390\/cancers12082278"},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"De Almeida, S., Regimbeau, M., Jego, G., Garrido, C., Girodon, F., and Hermetet, F. (2020). Heat Shock Proteins and PD-1\/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12092592"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.31557\/APJCP.2019.20.6.1691","article-title":"Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics","volume":"20","author":"Gilani","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/1078-0432.CCR-11-1541","article-title":"Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Maifrede","year":"2017","journal-title":"Blood"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood-2017-11-813006","article-title":"DNA distress creates lethal opportunity in MPN","volume":"130","author":"Tyner","year":"2017","journal-title":"Blood"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Braun, L.M., and Zeiser, R. (2020). Immunotherapy in Myeloproliferative Diseases. Cells, 9.","DOI":"10.3390\/cells9061559"},{"key":"ref_281","doi-asserted-by":"crossref","unstructured":"Alkharabsheh, O., and Frankel, A.E. (2019). Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies. Biomedicines, 7.","DOI":"10.3390\/biomedicines7010006"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"(2019). Testa; Pelosi; Castelli, CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2019-129397","article-title":"Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms","volume":"134","author":"Krishnan","year":"2019","journal-title":"Blood"},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Bose, P., Masarova, L., and Verstovsek, S. (2020). Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12102891"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"40141","DOI":"10.18632\/oncotarget.5653","article-title":"The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells","volume":"6","author":"Mazzacurati","year":"2015","journal-title":"Oncotarget"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","article-title":"The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN","volume":"3","author":"Mazzacurati","year":"2019","journal-title":"Blood Adv."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood.V128.22.1125.1125","article-title":"Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3K\u03b4 Inhibitor TGR-1202 in Myelofibrosis","volume":"128","author":"Moyo","year":"2016","journal-title":"Blood"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci. Signal."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined Targeting of JAK2 and Bcl-2\/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2019-130158","article-title":"Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"HemaSphere"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2019-127122","article-title":"PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN","volume":"134","author":"Pastore","year":"2019","journal-title":"Blood"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2018-99-118406","article-title":"Small-Molecule Inhibition of PRMT5 Induces Translational Stress and p53 in JAK2V617F Mutant Myeloproliferative Neoplasms","volume":"132","author":"Sonderegger","year":"2018","journal-title":"Blood"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/13543784.2016.1250882","article-title":"Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms","volume":"25","author":"Bose","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.exphem.2012.04.007","article-title":"The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells","volume":"40","author":"Todoerti","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood.V126.23.4060.4060","article-title":"Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)","volume":"126","author":"Harrison","year":"2015","journal-title":"Blood"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/path.5078","article-title":"Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis","volume":"245","author":"Gleitz","year":"2018","journal-title":"J. Pathol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"614","DOI":"10.12688\/f1000research.22554.1","article-title":"Neuronal regulation of bone marrow stem cell niches","volume":"9","author":"Fielding","year":"2020","journal-title":"F1000Research"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3324\/haematol.2018.211896","article-title":"Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms","volume":"104","author":"Herlihy","year":"2019","journal-title":"Haematologica"},{"key":"ref_306","first-page":"5","article-title":"Bone marrow fibrosis in primary myelofibrosis: Pathogenic mechanisms and the role of TGF-\u03b2","volume":"3","author":"Archana","year":"2016","journal-title":"Stem Cell Investig."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1111\/jcmm.15526","article-title":"Transforming growth factor \u03b2-mediated micromechanics modulates disease progression in primary myelofibrosis","volume":"24","author":"Teodorescu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"e90932","DOI":"10.1172\/jci.insight.90932","article-title":"Efficacy of ALK5 inhibition in myelofibrosis","volume":"2","author":"Yue","year":"2017","journal-title":"JCI Insight"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.exphem.2016.08.007","article-title":"Preclinical rationale for TGF-\u03b2 inhibition as a therapeutic target for the treatment of myelofibrosis","volume":"44","author":"Ceglia","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Yang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3389\/fimmu.2018.02328","article-title":"The Development of Serum Amyloid P as a Possible Therapeutic","volume":"9","author":"Pilling","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V126.23.56.56","article-title":"PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks","volume":"126","author":"Verstovsek","year":"2015","journal-title":"Blood"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2019.02.010","article-title":"Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"79","author":"Wang","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"e1433521","DOI":"10.1080\/2162402X.2018.1433521","article-title":"Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response","volume":"7","author":"Riley","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617Fcauses PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.18632\/oncotarget.6662","article-title":"Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression","volume":"7","author":"Pinton","year":"2016","journal-title":"Oncotarget"},{"key":"ref_319","unstructured":"John Mascarenhas, M., and Gabriela Hobbs, M.D. (2017). PD-1 Inhibition in Advanced Myeloproliferative Neoplasms."},{"key":"ref_320","unstructured":"Verstovsek, S. (2019). Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis."},{"key":"ref_321","unstructured":"Brady Stein, M. (2016). MHS, Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Martinenaite","year":"2018","journal-title":"Leukemia"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"key":"ref_324","unstructured":"Jacob, H., and Grauslund, M. (2018). CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study","volume":"105","author":"Mikkelsen","year":"2020","journal-title":"Haematologica"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2019-127119","article-title":"MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or \"Add-on\" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"ref_327","unstructured":"(2020). Study of Oral Navitoclax Tablet in Combination with Oral Ruxolitinib Tablet when Compared with Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants with Myelofibrosis (TRANSFORM-1)."},{"key":"ref_328","unstructured":"(2020). Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination with Oral Ruxolitinib Tablet in Adult Participants with Relapsed\/Refractory Myelofibrosis (TRANSFORM-2)."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"e20201268","DOI":"10.1084\/jem.20201268","article-title":"JAK2V617F myeloproliferative neoplasm eradication by a novel interferon\/arsenic therapy involves PML","volume":"218","author":"Dagher","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_330","doi-asserted-by":"crossref","unstructured":"Maslah1, N., Dagher, T., Edmond, V., Cassinat, B., Lallemand-Breitenbach, V., Verger, E., Plo, I., Kiladjian, J.-J., Villeval, J.-L., and de Th\u00e9, H. (2018). Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic. Blood, 132, 52.","DOI":"10.1182\/blood-2018-99-112518"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.exphem.2016.08.005","article-title":"Metformin inhibits JAK2V617F activity in MPN cells by activating AMPK and PP2A complexes containing the B56\u03b1 subunit","volume":"44","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41419-017-0256-4","article-title":"Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms","volume":"9","author":"Fenerich","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2019-130648","article-title":"Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)","volume":"134","author":"Campos","year":"2019","journal-title":"Blood"},{"key":"ref_334","doi-asserted-by":"crossref","unstructured":"Azizian, N.G., and Li, Y. (2020). XPO1-dependent nuclear export as a target for cancer therapy. J. Hematol. Oncol., 13.","DOI":"10.1186\/s13045-020-00903-4"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","article-title":"Nuclear\u2013Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis","volume":"25","author":"Yan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_336","unstructured":"Srinivas Tantravahi, M. (2018). Selinexor in Myelofibrosis Refractory or Intolerant to JAK1\/2 Inhibitors (ESSENTIAL)."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2018-08-872648","article-title":"CDK6 coordinates JAK2V617F mutant MPN via NF-\u03baB and apoptotic networks","volume":"133","author":"Uras","year":"2019","journal-title":"Blood"},{"key":"ref_338","doi-asserted-by":"crossref","unstructured":"Uras, I.Z., Sexl, V., and Kollmann, K. (2020). CDK6 Inhibition: A Novel Approach in AML Management. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072528"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1182\/blood-2019-132038","article-title":"The CDK6 Inhibitor Palbociclib in Combination with Ruxolitinib Remarkably Improves Myelofibrosis in Murine Models","volume":"134","author":"Mohi","year":"2019","journal-title":"Blood"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood.V128.22.953.953","article-title":"Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis","volume":"128","author":"Lu","year":"2016","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/659\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:09:51Z","timestamp":1760159391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":340,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22020659"],"URL":"https:\/\/doi.org\/10.3390\/ijms22020659","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]}}}